AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

We recently compiled a list of the 10 Stocks With At Least $10 Million In Insider Sales Recently. In this article, we are ...

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical ...

Eli Lilly plans a $27 billion investment to establish four manufacturing plants in the U.S., anticipated to generate 3,000 jobs for skilled workers and 10,000 construction jobs. The move aligns with ...

Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...

INDIANAPOLIS — Eli Lilly and Company is announcing a massive new set of investments in U.S. manufacturing. The company plans to more than double its investments since 2020, bringing the total to more ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...